{"id":"W3215701750","doi":"10.1007/s10549-021-06450-x","title":"Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Breast cancer; Internal medicine; Hazard ratio; Placebo; Paclitaxel; Taxane; Oncology; Clinical endpoint; Chemotherapy; Cancer; Gastroenterology; Randomized controlled trial; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007496868,0.0004131853,0.0008947041,0.00006742278,0.0003649446,0.00006701818,0.0003068862,0.0002114126,0.00007738845],"category_scores_gemma":[0.0002846194,0.0002911973,0.0003509233,0.0002992684,0.0007317793,0.00002297184,0.0002476166,0.0002485422,0.000001690314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007926134,"about_ca_system_score_gemma":0.002178876,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01240168,"about_ca_topic_score_gemma":0.001720148,"domain_scores_codex":[0.9961389,0.0008817526,0.0006390194,0.001040319,0.0006165639,0.0006834579],"domain_scores_gemma":[0.9968169,0.0006402119,0.0003326371,0.0007921637,0.001115234,0.0003027962],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7927228,0.001019248,0.0002114781,0.00003452076,0.001990903,0.00001092417,0.0003182459,0.00004905585,0.1693142,0.0000164713,0.002249087,0.03206308],"study_design_scores_gemma":[0.6440489,0.001939805,0.003924043,0.0003008515,0.0003354113,0.0000214837,0.0002498379,0.00008087111,0.3465038,0.0002046476,0.002009619,0.0003807114],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9119057,0.007861085,0.00009715852,0.002319355,0.0004340307,0.003984825,0.07321628,0.000015308,0.0001662717],"genre_scores_gemma":[0.9791358,0.01084094,0.000386943,0.0001278152,0.001029902,0.004324566,0.003196763,0.00006372807,0.0008935521],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1771896,"threshold_uncertainty_score":0.999954,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03520119051657982,"score_gpt":0.3610917612727934,"score_spread":0.3258905707562136,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}